United Kingdom· GB-APID-42652811000001106
Evkeeza 345mg/2.3ml concentrate for solution for infusion vials
A evinacumab product containing evinacumab, registered in United Kingdom by Ultragenyx UK Ltd. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Evinacumab is registered in 12 of 19 countries.
Countries holding a registration under ATC C10AX17 (evinacumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Evinacumab · ATC C10AX17
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Evinacumab
- Manufacturer
- Ultragenyx UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- C10AX17
- ATC class
- Evinacumab
- Defined daily dose
- 37.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin04062343002024
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Evinacumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumEvkeeza 150 mg/mlUltragenyx Germany
- CzechiaEVKEEZAUltragenyx Germany GmbH, Berlín
- United StatesEvkeezaRegeneron Pharmaceuticals, Inc.
- SpainEVKEEZA 150 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONUltragenyx Germany Gmbh
- FinlandEvkeezaUltragenyx Germany GmbH
- FranceEVKEEZA 150 mg/ml, solution à diluer pour perfusionULTRAGENYX GERMANY (ALLEMAGNE)
- IrelandEvkeeza 150 mg/ml concentrate for solution for infusionUltragenyx Germany GmbH
- IcelandEvkeezaUltragenyx Germany GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Evkeeza
- Liechtenstein · Evkeeza
- Norway · Evkeeza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7e6d59a5-36b9-469c-8ddc-15fd3730906b GET /v1/drugs/7e6d59a5-36b9-469c-8ddc-15fd3730906b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42652811000001106",
"desc": "Evkeeza 345mg/2.3ml concentrate for solution for infusion vials (Ultragenyx UK Ltd)",
"form": "Solution for infusion",
"vpid": "42655611000001103",
"source": "dmd",
"vtm_id": "1149185009",
"strength": "150 mg",
"substance": "Evinacumab",
"ingredient": "Evinacumab",
"supplier_code": "42640211000001106"
}See everything about evinacumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.